Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breakthrough Therapy Designation

- PMLiVE

Merck & Co says Januvia follow-up looking good

Diabetes drug shows promise in phase II as once-weekly treatment

Daiichi and ArQule pull late-stage study of lung cancer drug

Fails to reach primary endpoint of overall survival

Roche - Basel

Roche’s T-DM1 activity in breast cancer “outstanding”

Improves survival by six months compared to GSK’s Tykerb/Tyverb

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

European approvals for J&J cancer treatments

EC passes new Dacogen indications and backs subcutaneous Velcade

- PMLiVE

AZ launches science blog LabTalk

Hopes new blog will build relationships with potential collaborators

- PMLiVE

Bayer gets US green light for colorectal cancer drug Stivarga

Follows FDA approval for Sanofi and Regeneron's Zaltrap in same indication

- PMLiVE

Developing drugs to conquer cancer

Future treatments for suppression of antitumour activity, metastatic melanoma and NSCLC were showcased at ASCO 2012 with some exciting results

- PMLiVE

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs

Incivo and Victrelis joint winners of Innovative Product Award

- PMLiVE

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs

Incivo and Victrelis joint winners of Innovative Product Award

- PMLiVE

This month in 1901: Birth of Charles Brenton Huggins

This month in pharma: September 1901, the birth of the man who linked hormones with cancer

- PMLiVE

Boehringer cancer R&D programme bears first fruit

Submits afatinib in Europe to treat lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links